AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28349578 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist recommendations adopted by physicians.
Number of subjects: 104
Study 27604812 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and parenteral antibiotics
Number of subjects: 582
Study 27604812 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal surgery
Number of subjects: 582
Study 27604812 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon surgery
Number of subjects: 582
Study 25047900 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailoring + online video-coaching
Number of subjects: 0
Study 25047900 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailoring-only
Number of subjects: 0
Study 25047900 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 21950458 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (100mg three times daily for 7 days)
Number of subjects: 12
Study 21950458 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine (60mg alone)
Number of subjects: 12
Study 20130569 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg daily
Number of subjects: 305
Study 18454423 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued PCNL (Group 1)
Number of subjects: 31
Study 18454423 — intervention group
Group type: COMPARATOR
Intervention: Delayed PCNL (Group 2)
Number of subjects: 31
Study 18454423 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 31
Study 18454423 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative outcomes
Number of subjects: 31
Study 16733286 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage surgical repair of the cleft lip and palate performed in the first year of life
Number of subjects: 25
Study 16733286 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal morphology of the dental arches)
Number of subjects: 25
Study 11476257 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin (2% solution)
Number of subjects: 39
Study 11476257 — intervention group
Group type: COMPARATOR
Intervention: Morphine (3% solution)
Number of subjects: 39
Study 9609749 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 2302 (0.5, 1, or 2 mg/kg)
Number of subjects: 20
Study 9609749 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 20
Study 9609749 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 2302
Number of subjects: 20
Study 7819717 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniaturized lithotripter (group B)
Number of subjects: 73
Study 7819717 — intervention group
Group type: COMPARATOR
Intervention: Conventional electromagnetic lithotripter (group A)
Number of subjects: 73
Study 2457072 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsphere pancreatic enzyme preparations (Pancrease, Creon)
Number of subjects: 0
Study 2457072 — intervention group
Group type: COMPARATOR
Intervention: Conventional enzyme preparation (Pancrex V Forte)
Number of subjects: 0
Study 2457072 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsphere pancreatic enzyme preparations (Pancrease, Creon, pancreatin Merck)
Number of subjects: 0
Study 2457072 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsphere pancreatic enzyme preparations (Creon)
Number of subjects: 0
Study 1773226 — intervention group
Group type: EXPERIMENTAL
Intervention: Polythene sheet dressing
Number of subjects: 0
Study 1773226 — intervention group
Group type: COMPARATOR
Intervention: Jelonet dressing
Number of subjects: 0
Study 201592 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 10
Study 201592 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy after clinical deterioration
Number of subjects: 10
Study 201592 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 10
Study 30246926 — intervention group
Group type: EXPERIMENTAL
Intervention: EpiCord
Number of subjects: 155
Study 30246926 — intervention group
Group type: COMPARATOR
Intervention: Alginate dressings
Number of subjects: 155
Study 27056686 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) × 2 doses
Number of subjects: 102
Study 27056686 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) single dose
Number of subjects: 102
Study 27056686 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone × 4 doses
Number of subjects: 102
Study 25543089 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (IFNβ) treatment
Number of subjects: 277
Study 25543089 — intervention group
Group type: COMPARATOR
Intervention: Transient NAbs
Number of subjects: 277
Study 25543089 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained NAbs
Number of subjects: 277
Study 23632747 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein 4.5g
Number of subjects: 12
Study 23632747 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein 9g
Number of subjects: 12
Study 23632747 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein 18g
Number of subjects: 12
Study 23632747 — intervention group
Group type: COMPARATOR
Intervention: Glucose in water (reference)
Number of subjects: 12
Study 21859185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 125
Study 21859185 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss (BWL)
Number of subjects: 125
Study 21859185 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + BWL (sequential treatment)
Number of subjects: 125
Study 19688321 — intervention group
Group type: EXPERIMENTAL
Intervention: Yangyin Humo Decoction (YHD)
Number of subjects: 42
Study 16702981 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (C)
Number of subjects: 36913
Study 16702981 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (A)
Number of subjects: 36913
Study 16702981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (L)
Number of subjects: 36913
Study 16702981 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (D)
Number of subjects: 36913
Study 16702981 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (A) + Lisinopril (L)
Number of subjects: 36913
Study 15084389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin + vinorelbine 25 mg/m2 days 1, 8 and 15
Number of subjects: 36
Study 15084389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin + gemcitabine 1000 mg/m2 days 1, 8 and 15
Number of subjects: 36
Study 15084389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin + paclitaxel 200 mg/m2 day 1 iv over 1h
Number of subjects: 36
Study 15084389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin + etoposide 100 mg/m2 po days 1-6
Number of subjects: 36
Study 11591082 — intervention group
Group type: EXPERIMENTAL
Intervention: One of four combinations of devices
Number of subjects: 0
Study 11591082 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study 9602594 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 48
Study 9602594 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 48
Study 9602594 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 48
Study 7889961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil, given once or twice daily
Number of subjects: 0
Study 7889961 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor, amoxicillin‐clavulanate, or erythromycin
Number of subjects: 0
Study 2606428 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg
Number of subjects: 9
Study 2606428 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 1.0 mg
Number of subjects: 9
Study 2606428 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 1.5 mg
Number of subjects: 9
Study 30879375 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-Not-Burn cigarettes (HNBC)
Number of subjects: 20
Study 30879375 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Vaping Cigarettes (EVC)
Number of subjects: 20
Study 27881381 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated 6-week weightbearing (AR group)
Number of subjects: 35
Study 27881381 — intervention group
Group type: COMPARATOR
Intervention: Current best practice 8-week weightbearing (CR group)
Number of subjects: 35
Study 26115189 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block (2‐day ropivacaine 0.2% infusion)
Number of subjects: 30
Study 26115189 — intervention group
Group type: COMPARATOR
Intervention: Continuous femoral nerve block (2‐day ropivacaine 0.2% infusion)
Number of subjects: 30
Study 26115189 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block
Number of subjects: 30
Study 26115189 — intervention group
Group type: COMPARATOR
Intervention: Continuous femoral nerve block
Number of subjects: 30
Study 23963284 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention 'Living to the full'
Number of subjects: 206
Study 21471907 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for nurses in guided self-help intervention
Number of subjects: 10
Study 21471907 — intervention group
Group type: COMPARATOR
Intervention: No training for nurses (control)
Number of subjects: 10
Study 19217807 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning (mechanical or pharmacological manipulation)
Number of subjects: 0
Study 19217807 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 0
Study 16953000 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD) induced by administration of capsules containing an amino acid mixture without tryptophan.
Number of subjects: 53
Study 16953000 — intervention group
Group type: COMPARATOR
Intervention: Sham depletion using identical capsules containing lactose.
Number of subjects: 53
Study 16953000 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 53
Study 16953000 — intervention group
Group type: COMPARATOR
Intervention: Sham depletion
Number of subjects: 53
Study 15575909 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol 0.25 microg daily
Number of subjects: 30
Study 15575909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11685731 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone (30 mg/m² intravenously, every 7 days for 3 weeks)
Number of subjects: 59
Study 11685731 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus thalidomide (200 mg at bedtime)
Number of subjects: 59
Study 9463599 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 0
Study 9463599 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 7947128 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal medication record card
Number of subjects: 0
Study 7947128 — intervention group
Group type: COMPARATOR
Intervention: Control group (no card)
Number of subjects: 0
Study 3283061 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (30 mg, three times a day)
Number of subjects: 22
Study 3283061 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg, three times a day)
Number of subjects: 22
Study 3283061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30558033 — intervention group
Group type: EXPERIMENTAL
Intervention: CG-CAHPS questions (reporting)
Number of subjects: 61115
Study 30558033 — intervention group
Group type: EXPERIMENTAL
Intervention: Press Ganey questions (rating)
Number of subjects: 61115
Study 26908539 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose influenza vaccine
Number of subjects: 53035
Study 26908539 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose influenza vaccine
Number of subjects: 53035
Study 24215485 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose ZDV/3TC/abacavir (TZV)
Number of subjects: 0
Study 24215485 — intervention group
Group type: COMPARATOR
Intervention: CBV/LPV/r
Number of subjects: 0
Study 22719231 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 500
Study 22719231 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 500
Study 20435936 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.035 to 0.05 mg x kg(‐1) IV for 1 minute followed by an infusion of 0.035 to 0.05 mg x kg(‐1) x h(‐1) for 59 minutes)
Number of subjects: 8
Study 20435936 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam with propofol (target‐controlled infusion of propofol at constant C(T): 0.6 or 1.0 microg x mL(‐1))
Number of subjects: 8
Study 20435936 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (C(blood): 1.2 microg x mL(‐1))
Number of subjects: 8
Study 18306161 — intervention group
Group type: EXPERIMENTAL
Intervention: LED treatments (660 nm)
Number of subjects: 15
Study 18306161 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (non-treated sites)
Number of subjects: 15
Study 15823945 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8‐16 mg daily
Number of subjects: 4937
Study 12365701 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude-scaled accommodative facility testing in children
Number of subjects: 250
Study 12365701 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard accommodative facility testing in children
Number of subjects: 250
Study 12365701 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude-scaled accommodative facility testing in adults
Number of subjects: 250
Study 12365701 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard accommodative facility testing in adults
Number of subjects: 250
Study 10069091 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic intervention (individual sessions, audiotapes) designed to augment fracture healing.
Number of subjects: 11
Study 10069091 — intervention group
Group type: COMPARATOR
Intervention: Standard orthopedic care (control group).
Number of subjects: 11
Study 8850384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dopexamine at a rate of 0.5 micrograms/kg/min, titrated to achieve a 30% or more increase in cardiac index
Number of subjects: 20
Study 8850384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2209343 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of glipizide (20 mg before breakfast and dinner) and human proinsulin (subcutaneously at bedtime)
Number of subjects: 15
Study 2209343 — intervention group
Group type: COMPARATOR
Intervention: Glipizide (20 mg before breakfast and dinner) and human proinsulin placebo
Number of subjects: 15
Study 2209343 — intervention group
Group type: COMPARATOR
Intervention: Glipizide placebo and human proinsulin
Number of subjects: 15
Study 7243605 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg peptide analog of ACTH/MSH 4-9
Number of subjects: 0
Study 7243605 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg peptide analog of ACTH/MSH 4-9
Number of subjects: 0
Study 7243605 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg peptide analog of ACTH/MSH 4-9
Number of subjects: 0
Study 7243605 — intervention group
Group type: COMPARATOR
Intervention: 0 mg peptide analog of ACTH/MSH 4-9 (placebo)
Number of subjects: 0
Study 7243605 — intervention group
Group type: EXPERIMENTAL
Intervention: peptide analog of ACTH/MSH 4-9 (all doses)
Number of subjects: 0
Study 31605549 — intervention group
Group type: EXPERIMENTAL
Intervention: COMDQ-15 (short version of the Chronic Oral Mucosal Disease Questionnaire)
Number of subjects: 520
Study 31605549 — intervention group
Group type: EXPERIMENTAL
Intervention: COMDQ-15
Number of subjects: 520
Study 30952483 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative conversation and shared decision making regarding surgery and palliative care
Number of subjects: 0
Study 30952483 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning and goals of care discussions
Number of subjects: 0
Study 28820084 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy meals and water availability during work hours
Number of subjects: 60
Study 28820084 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy meals and water availability during work hours (shift workers)
Number of subjects: 60
Study 28820084 — intervention group
Group type: COMPARATOR
Intervention: Control period (no healthy meals and water)
Number of subjects: 60
Study 27545448 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once daily until postoperative day 5
Number of subjects: 298
Study 27545448 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin 2000 units twice daily until postoperative day 5
Number of subjects: 298
Study 27545448 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 298
Study 27545448 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin
Number of subjects: 298
Study 24998677 — intervention group
Group type: EXPERIMENTAL
Intervention: Netprotect
Number of subjects: 0
Study 24998677 — intervention group
Group type: COMPARATOR
Intervention: PermaNet 2.0 (positive control)
Number of subjects: 0
Study 23364217 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day indisetron regimen
Number of subjects: 42
Study 23364217 — intervention group
Group type: COMPARATOR
Intervention: 1-day indisetron regimen
Number of subjects: 42
Study 20031131 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate (HC) meal
Number of subjects: 0
Study 20031131 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat (HF) meal
Number of subjects: 0
Study 20031131 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein (HP) meal
Number of subjects: 0
Study 20031131 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (not specified meal type)
Number of subjects: 0
Study 18211609 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antioxidant treatment with vitamin C and alpha-glucosylrutin
Number of subjects: 20
Study 15926437 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluoride gel applied prior to acid etching (test group)
Number of subjects: 70
Study 15926437 — intervention group
Group type: COMPARATOR
Intervention: Fissure sealant applied without prior fluoride treatment (control group)
Number of subjects: 70
Study 12800810 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion treatment for six sessions over a 3-week period
Number of subjects: 15
Study 10479134 — intervention group
Group type: EXPERIMENTAL
Intervention: MN rgp120 vaccine
Number of subjects: 26
Study 10479134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8759414 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HTZ: 25 mg o.d.)
Number of subjects: 55
Study 8759414 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PRO: 40 mg t.i.d.)
Number of subjects: 55
Study 7694894 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b (3 million units, three times a week, subcutaneously for 48 weeks)
Number of subjects: 80
Study 7694894 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha 2b (3 million units, three times a week, subcutaneously for 24 weeks)
Number of subjects: 80
Study 7694894 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term responders
Number of subjects: 80
Study 7694894 — intervention group
Group type: COMPARATOR
Intervention: Non-responders
Number of subjects: 80
Study 2862619 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynanthine 2%
Number of subjects: 10
Study 2862619 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynanthine 5%
Number of subjects: 10
Study 2862619 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynanthine 1%
Number of subjects: 10
Study 2862619 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynanthine 2% (applied two or three times daily for one, two, or three weeks)
Number of subjects: 10
Study 31630538 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact force-guided radiofrequency ablation (CF-RF)
Number of subjects: 346
Study 31630538 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-minute cryoballoon ablation (Cryo-4)
Number of subjects: 346
Study 31630538 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-minute cryoballoon ablation (Cryo-2)
Number of subjects: 346
Study 29475793 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine alone
Number of subjects: 0
Study 29475793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine alone
Number of subjects: 0
Study 29475793 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine plus haloperidol
Number of subjects: 0
Study 29475793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine plus haloperidol
Number of subjects: 0
Study 29475793 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 29475793 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and nicotine combined with haloperidol
Number of subjects: 0
Study 27306792 — intervention group
Group type: COMPARATOR
Intervention: OTL38 (near-infrared fluorescent agent) administered intravenously in increasing doses.
Number of subjects: 42
Study 27306792 — intervention group
Group type: EXPERIMENTAL
Intervention: OTL38 administered intravenously to patients with ovarian cancer.
Number of subjects: 42
Study 24622029 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-fit group (activated 5 days post-surgery)
Number of subjects: 23
Study 24622029 — intervention group
Group type: COMPARATOR
Intervention: Standard-fit group (activated after recommended waiting period)
Number of subjects: 23
Study 24622029 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-fit group
Number of subjects: 23
Study 24622029 — intervention group
Group type: COMPARATOR
Intervention: Standard-fit group
Number of subjects: 23
Study 24926548 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m intravenous every 21 days) with PX-866 (8 mg orally daily)
Number of subjects: 95
Study 24926548 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m intravenous every 21 days) without PX-866
Number of subjects: 95
Study 22814125 — intervention group
Group type: EXPERIMENTAL
Intervention: bPImono (n=88)
Number of subjects: 192
Study 22814125 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (CT) (n=85)
Number of subjects: 192
Study 22814125 — intervention group
Group type: EXPERIMENTAL
Intervention: bPImono (n=94)
Number of subjects: 192